Utilizing transcriptomic profiling of patient-derived pancreatic tumor organoids, it was discovered that CK21, a novel triptolide analog, downregulates the NF-κB pathway and induces tumor cell apoptosis, suggesting a possible biomarker to target for pancreatic cancer treatment [90]. The gene discussed is NFKB1; the disease is pancreatic neoplasm.